Dr. Kuldeep Neote is a trained molecular biologist with an extensive background in drug discovery. He has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs.
Currently, Kuldeep serves as Entrepreneur in Residence of Commercialization at UHN, as well as at the National Institutes of Health and part-time at FACIT/OICR. Formerly, Kuldeep was Vice President External Innovation at the Eli Lilly and Company, Boston; Senior Director, New Ventures at Johnson & Johnson Innovation and was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech.
Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a PhD in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.
